Phase 2 Registrational Study of Anitocabtagene Autoleucel for Relapsed and/or Refractory Multiple Myeloma (RRMM): Updated Results from iMMagine-1
Gurbakhash Kaur(The University of Texas Southwestern Medical Center), Matthew J. Frigault(Harvard University), Tim Welliver, Carolyn Jackson, Enrique Granados, Cindy Varga, Larry D. Anderson(Dana-Farber Cancer Institute), Natalie S. Callander(University of Wisconsin–Madison), Carolina Schinke(University of Arkansas for Medical Sciences), Abhinav Deol(Wayne State University), Noa Biran(Hackensack University Medical Center), Douglas W. Sborov(University of Utah), Mehmet H. Kocoglu(University of Maryland, Baltimore), Krishna Rana(Gilead Sciences (Australia)), Ciara L. Freeman(Moffitt Cancer Center), Abraham S. Kanate(HonorHealth), Adam S. Sperling(Dana-Farber Cancer Institute), Richard T. Maziarz(Oregon Health & Science University), Andrzej Jakubowiak(University of Chicago), Christopher R. Heery(National Cancer Institute), Binod Dhakal(Medical College of Wisconsin), Krina Patel(The University of Texas MD Anderson Cancer Center), Melhem Solh(Johns Hopkins Hospital), Ana Kostić(Agriculture and Agri-Food Canada), Kamalika Banerjee(XCell Science (United States))
Cited by 0
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
Efficacy of Tocilizumab in Patients Hospitalized with Covid-19
|New England Journal of Medicine|2020|1.4k
Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
|New England Journal of Medicine|2012|1.2k